首页 行业资源正文

岸迈生物 epimab

EpimAb_Logo_reversed.jpg

岸迈生物是一家医疗健康公司,产品开发主要关注的领域是肿瘤,主要业务是双特异性抗体研发。岸迈生物自主研发的FIT-Ig技术是一项独特高效的开发双特异性抗体产品的创新平台技术。


Our FIT-Ig (Fabs-In-Tandem) technology is based on the scientific rationale to combine the functions of two parental antibodies into one single molecule. This is achieved by re-arranging the DNA sequences of two monoclonal antibodies into three constructs and co-expressing them in mammalian cells. Our unique approach requires no Fc mutation; no scFv elements; and no linker or peptide connector. The Fab-domains in each arm work “in tandem” forming a tetravalent bi-specific antibody with four active and independent antigen binding sites that fully retain the biological function of their parental antibodies. By increasing the variety of FIT-Ig molecules further, EpimAb plans to build up technical know-how and generate additional scientific insights to explore the unique features and overall capabilities of this new drug format.


EpimAb’s lead candidate, EMB-01 has shown that the FIT-Ig format can also achieve significant efficacy superior to separate antibodies as well as their open combination. Read more here.


岸迈生物科技(苏州)有限公司

上海岸迈生物科技有限公司


http://www.epimab.com/

电话:021-61043290

邮箱:cw@epimab.com

本文地址:岸迈生物 epimab https://www.5zhi.org/post/22.html